


## ■ BT-474 cells

Human BT-474 cells were isolated from the mammary gland of a patient with breast ductal carcinoma.

## ■ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing BT-474 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




**Figure 1:** Tumour growth curve of the BT-474 cells as xenograft  
Mean  $\pm$  SEM (n=6; take rate 100%)

Antineo can also implant this model orthotopically.

## ■ Standard-Of-Care Drug Responses

T-DM1 3 mg/kg  $\rightarrow$  Response



**Figure 2:** Effect of T-DM1 treatment on BT-474 tumour growth  
Mean  $\pm$  SEM (n=10 per group; take rate 100%)

**A BT474 resistant to T-DM1  
model, developed *in vivo*  
without genetic modifications,  
are available at Antineo (model  
ID BT474 TDM1R).**